A new baby-friendly dispersible anti-malarial is born
3 out of 4 deaths from malaria occur in children under age five. Malaria affects even the tiniest infants. Malaria is also known to influence neurocognitive development in young infants and affects a child’s health long after infancy. Malaria is also a cause of infant mortality.
A drug formulation, Coartem® (artemether-lumefantrine) Baby, also known as Riatem Baby, is newly approved as a treatment for infants as of July 2025. The pharmaceutical is dispersible meaning it can be dissolved in another liquid, including breastmilk.
The two compounds that comprise Coartem were developed in China in the 1970s, following the isolation of artemether from artmesinin (naturally found in wormwood).
Novartis acquired the rights to the compounds and created the brand name Coartem in 1999. By 2004 the World Health Organization approved the dual formulation as the first fixed-dosed artemisinin. However, use in infants was still uncharted.
“Launched on 6 December 2007, 'Make medicines child size' is a five-year global campaign spearheaded by the World Health Organization (WHO) [1]. The aim is to raise awareness and accelerate action to address the need for improved availability and access to safe and effective child-specific medicines for all children under the age of 15.”
By 2009 researchers were testing the dispersible Coartem tablet to see if it was not inferior to the crushed tablets already being used. It was not inferior.
The next step was to address the bitter flavor of the antimalarials. A study in Tanzanian schoolchildren compared an oral suspensions of strawberry, orange and cherry. The clear winner was cherry.
Next was a phase III clinical trial testing Coartem in infants under and over 28 days and weighing more than 5 kg (NCT04300309) with uncomplicated facliparum malaria.
The results of this trial were that the pharmacokinetic endpoints of the trial were met. In other words, the medicine worked.
Eight countries Burkina Faso, Cote d’Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda accounted for 47 percent of malaria in 2023. These eight countries are now expected to approve the new medicine for use in their countries.
Sources
Abdulla S, Sagara I. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. Malar J. 2009 Oct 12;8 Suppl 1(Suppl 1):S7. doi: 10.1186/1475-2875-8-S1-S7. PMID: 19818174; PMCID: PMC2760242.
https://www.nature.com/articles/s41598-025-94800-w
https://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-8-S1-S7
Leave a comment
Comments will be approved before showing up.
Also in The Maternova Blog
Pumani bubble CPAP
The Pumani bubble CPAP was engineered by a team at Rice University in Texas, working in collaboration with clinicians in Malawi. A range of specific design considerations made the Pumani especially appropriate for low-resource settings so that parts are easy to replace.
The MaternaWell Tray for PPH estimation now appears in key obstetric guidelines
A 'tray' is now mentioned in the FIGO/WHO/ICM Consolidated Postpartum Hemorrhage Guidelines published by in 2025, expanding the type of monitoring device from drape to drape or tray.
Is it ethical to separate mother and infant just after birth?
Immediate skin to skin care means less than ten minutes after the infant takes its first breath, the infant, naked except for a diaper, spends at least one hour on the mother’s chest, against her skin. It is recommended that preterm and low birth weight kangaroo care involve prolonging contact beyond the first hour for at least 8 hours per day or as long as possible (up to 24 hours) per day
